Lexaria Bioscience Corp.

83 articles about Lexaria Bioscience Corp.

• Lexaria is Receiving Four New Patents

  4/20/2023

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces that it has received notifications of four new patents either awarded or allowed.

• Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4

  2/21/2023

  Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 ("the Study") demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol ("CBD") capsule formulation in reducing blood pressure ("BP").

• Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels

  12/21/2022

  Lexaria Bioscience Corp. is pleased to announce it has demonstrated superior cannabidiol ("CBD") blood absorption levels from its patented DehydraTECH-CBD™ relative to those of published, pharmaceutical-grade CBD industry comparators in its recently completed, multi-week human clinical hypertension study HYPER-H21-4.

• Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program

  11/29/2022

  Lexaria Bioscience Corp. announces that its patented DehydraTECH-CBD has demonstrated performance enhancements compared to one of the world's leading anti-seizure medications, Epidiolex.

• Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study

  11/1/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that independent review board approval has now been received for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon.

• Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors

  9/2/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that Catherine Turkel, PharmD, PhD has joined the board of directors of Lexaria Bioscience Corp.

• Lexaria Receives New Patent in Mexico

  8/31/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its 27th worldwide patent granted in Mexico under registration #390001.

• 

  FDA Review: Bayer, Daiichi Sankyo, AstraZeneca and More

  8/12/2022

  Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.

• Lexaria Discusses Valuation Metrics for Biotech Industry

  8/11/2022

  Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

• Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution

  8/11/2022

  NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.”.

• Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension

  8/10/2022

  Lexaria Bioscience Corp. is pleased to announce that it has received a positive full written response from the Food and Drug Administration from its pre-Investigational New Drug ("Pre-IND") meeting regarding DehydraTECH-CBD for the treatment of hypertension.

• Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension

  8/9/2022

  Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

• Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing

  7/14/2022

  Lexaria Bioscience Corp. is pleased to announce the Company has been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan.

• Lexaria's Human Nicotine Study Nearing Start Date

  7/13/2022

  Lexaria Bioscience Corp. announces the pending start of its upcoming human nicotine study NIC-H22-1.

• Lexaria Signs Manufacturing and License Agreements with BevNology

  6/21/2022

  Lexaria Bioscience Corp. is pleased to announce the signing of two agreements with Atlanta-based BevNology LLC ("BevNology").

• Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market

  6/3/2022

  Lexaria Bioscience Corp. is pleased to announce a significant exclusive* commercial licensing agreement in Japan with Premier Wellness Science Co., Ltd., ("Premier").

• Lexaria Grants License to Valcon Medical for the European Market

  6/2/2022

  Lexaria Bioscience Corp. is pleased to announce the awarding of a European and United Kingdom DehydraTECH license for medical cannabis applications from Lexaria Pharmaceutical Corp. to Valcon Medical A/S ("Valcon").

• Lexaria Announces 2022 Annual Meeting Results

  6/1/2022

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting.

• Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

  5/26/2022

  Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”

• Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

  5/25/2022

  Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.